Here are five highlights:
1. Seventy-one percent of Ampion-treated patients met the OMERACT-OARSI responder criteria, beating the 30 percent threshold to be classified a meaningful treatment for severe knee osteoarthritis.
2. Ampion-treated patients experienced a 53 percent decrease in pain and a 50 percent improvement in function. Additionally, patients reported a 45 percent improvement in quality of life.
3. Ampion is the first intra-articular injection to treat knee osteoarthritis.
4. Ampion has been administered to more than 900 patients throughout each phase of the clinical trial. No patients reported drug related treatment-emergent adverse events.
5. The company plans to distribute more details about the phase 3 clinical trial at an upcoming scientific meeting. The company will submit results for publication as well.
More articles on devices and implants:
Medtronic, NuVasive, Stryker & more: 13 device company notes
Wright Medical acquires software solutions developer for shoulder replacement planning: 6 key notes
NuVasive appoints Michael Piccirillo to lead global surgeon education platform: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
